The US Food and Drug Administration first approved intraarticular hyaluronic acid injections (also known as viscosupplementation) in 1997 to treat patients with severe knee osteoarthritis. The effectiveness of these injections, however, has recently been questioned. In 2013, the American Academy of Orthopedic Surgeons issued a clinical practice guideline that stated, "We cannot recommend using hyaluronic acid for patients with symptomatic [osteoarthritis] of the knee," with a "strong" rating. 1 The rating was based on high-quality evidence that hyaluronic acid injections were not associated with clinically meaningful improvement in symptoms compared with placebo injections. A meta-analysis published in 2012 reported similar findings. 2 Using recent Medicare Part B claims
data, we examined patterns of use for intra-articular hyaluronic acid injections across the United States.
Methods | We analyzed 2012 Medicare Provider Utilization and Payment Data, which is available for public use. The data file contains all Part B claims for the Medicare fee-for-service population, aggregated by provider, with certain exclusions. 3 We tabulated injections ("bene-days") with all formulations of hyaluronic acid (Healthcare Common Procedure Coding System codes J7321, J7323, J7324, J7325, and J7326) according to health referral region (HRR; large regionalized health care markets defined by patients' travel for tertiary care). 4 We calculated total payments by Medicare from reported payments to each provider for (1) hyaluronic acid products and (2) the associated Current Procedural Terminology code for large-joint injections (20610). If multiple injections were given on the same day to a single patient, only 1 was counted. Using data from the Dartmouth Atlas of Health Care, we divided the raw totals for the number of hyaluronic acid injections by the total number of Medicare beneficiaries in each HRR. 4 We used logistic regression to correlate the number of procedures performed in each HRR (per 1000 beneficiaries) with the number of physicians per capita. 5 We applied previously described methods to assess clustering among high-use regions.
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Aggregated records derived from 10 or fewer beneficiaries were excluded from this public use file. The data set also did not contain information on individual patients, including indications for treatment. The institutional review boards at our institutions exempted the study from review.
Results | In 2012, Medicare Part B reimbursed for 1 161 924 injections with intra-articular hyaluronic acid among 423 669 patients by 12 761 physicians or other clinicians. Most formulations of hyaluronic acid consist of 3 injections given 1 week apart. Medicare paid $207 million for the hyaluronic acid product and $80 million for the associated large-joint injection (identified by the Current Procedural Terminology code). Thus, the average cost per injection paid by Medicare was $179 for the drug and $69 for the injection. The clinicians most likely to give intra-articular hyaluronic acid were orthopedic surgeons (59%), primary care physicians (11%, including family, general, internal, and geriatric medicines), physician assistants (10%), and rheumatologists (8%). An analy- Letters sis by HRRs showed that rates of intra-articular hyaluronic acid injections varied from 1 to 115 injections per 1000 Medicare beneficiaries (mean, 39/1000 Medicare beneficiaries; coefficient of variation, 56% [Figure] ). These HRRs were clustered (P < .001). Higher rates of injection of intra-articular hyaluronic acid in an HRR were associated with higher numbers of physicians, surgeons, and rheumatologists (adjusted for population size) but were not correlated with the number of orthopedists (Table) .
Discussion | In the United States in 2012, intra-articular hyaluronic acid was given frequently to Medicare beneficiaries despite strong evidence that this treatment is of low value for its approved indication of severe knee osteoarthritis. The injections are costly and have limited clinical benefit. We also found that the frequency of use varied widely and was correlated with the number of physicians, but not the number of orthopedic surgeons, in a region. One limitation of our study is that we could not determine the indications for treatment, such as the percentage of injections given to patients with severe knee osteoarthritis. We also could not determine if any patients developed infections or other complications.
Based on recent guidelines and studies, intra-articular hyaluronic acid injections represent low-value care and an inefficient use of health care resources.
2,3 Medicare beneficiaries and society would be better served if physicians and others involved in delivering and paying for health care worked together to minimize the use of such low-value care.
1. 
Trends in Boxed Warnings and Withdrawals for Novel Therapeutic Drugs, 1996 Through 2012
Boxed warnings describe potentially life-threatening risks associated with certain prescription drugs. 1 The warnings are surrounded by a border or "box" in the drug label and may be present at the time of drug approval (ie, a premarket warning) or added during the postmarket period (ie, a postmarket warning). Despite the use of boxed warnings for the most serious adverse reactions, trends and associated predictors for such warnings have not been well characterized. The objective of this study was to determine the frequency of premarket and postmarket boxed warnings and safety-related withdrawals for novel therapeutics approved between 1996 and 2012.
Methods | Institutional review board approval was waived by the University of California, San Francisco, Committee on Human Research. All drug labeling histories, boxed-warningrelated safety announcements, and safety-related withdrawals associated with novel therapeutics (ie, new pharmacological or biological molecular entities) approved between 1996 and 2012 were reviewed. Primary data sources were the Center for Drugs Evaluation and Research (CDER) and Medwatch websites 2,3 ; the Physicians' Desk Reference was used for historic labels unavailable online. Approval date, presence or absence of a premarket warning, and date of US Food and Drug Administration (FDA) communications issued between 1996 and 2013 for a safety-related withdrawal or addition of new safety risks to a boxed warning were recorded. Median times to first postmarket boxed warning or withdrawal based on presence or absence of a premarket boxed warning were calculated and compared using the Wilcoxon rank sum test. Descriptive statistics were used to examine patterns in drug type (pharmacological or biological) and approval year (before or after 2004, the study midpoint). Multiple logistic regression analyses were used to estimate the likelihood of a boxed warning based on drug type and approval year. We used SAS version 9.3 (SAS Institute Inc) for statistical analyses, and P < .05 was considered statistically significant.
Results | There were 522 novel therapeutics approved during our study, including 441 pharmacological and 81 biological products. One hundred eighty had ever received a boxed warning (136 pharmacological and 44 biological products); 105 had only received premarket warnings, 50 only acquired postmarket warnings, and 25 had both (eTable 1 in the Supplement). In total, there were 89 postmarket boxed warnings, and 11 withdrawals (eTable 2 in the Supplement), most of which (81%) occurred after 2004 (Figure, A) . Premarket warnings were more common among biological than pharmacological products (31% vs 22%, respectively; odds ratio, 2.0, 95% CI, 1.2-3.3) and among drugs 
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